|
1
|
O'Driscoll L and Clynes M: Biomarkers and
multiple drug resistance in breast cancer. Curr Cancer Drug
Targets. 6:365–384. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coley HM: Mechanisms and strategies to
overcome chemotherapy resistance in metastatic breast cancer.
Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arosio P, Adelman TG and Drysdale JW: On
ferritin heterogeneity. Further evidence for heteropolymers. J Biol
Chem. 253:4451–4458. 1978.PubMed/NCBI
|
|
4
|
Boyd D, Vecoli C, Belcher DM, Jain SK and
Drysdale JW: Structural and functional relationships of human
ferritin H and L chains deduced from cDNA clones. J Biol Chem.
260:11755–11761. 1985.PubMed/NCBI
|
|
5
|
Levi S, Yewdall SJ, Harrison PM,
Santambrogio P, Cozzi A, Rovida E, Albertini A and Arosio P:
Evidence of H- and L-chains have co-operative roles in the
iron-uptake mechanism of human ferritin. Biochem J. 288:591–596.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cozzi A, Corsi B, Levi S, Santambrogio P,
Albertini A and Arosio P: Overexpression of wild type and mutated
human ferritin H-chain in HeLa cells: In vivo role of ferritin
ferroxidase activity. J Biol Chem. 275:25122–25129. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Macip S, Igarashi M, Berggren P, Yu J, Lee
SW and Aaronson SA: Influence of induced reactive oxygen species in
p53-mediated cell fate decisions. Mol Cell Biol. 23:8576–8585.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wade VJ, Levi S, Arosio P, Treffry A,
Harrison PM and Mann S: Influence of site-directed modifications on
the formation of iron cores in ferritin. J Mol Biol. 221:1443–1452.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lawson DM, Treffry A, Artymiuk PJ,
Harrison PM, Yewdall SJ, Luzzago A, Cesareni G, Levi S and Arosio
P: Identification of the ferroxidase centre in ferritin. FEBS Lett.
254:207–210. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alkhateeb AA, Han B and Connor JR:
Ferritin stimulates breast cancer cells through an iron-independent
mechanism and is localized within tumor-associated macrophages.
Breast Cancer Res Treat. 137:733–744. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cozzi A, Corsi B, Levi S, Santambrogio P,
Biasiotto G and Arosio P: Analysis of the biologic functions of H-
and L-ferritins in HeLa cells by transfection with siRNAs and
cDNAs: Evidence for a proliferative role of L-ferritin. Blood.
103:2377–2383. 2004. View Article : Google Scholar
|
|
12
|
Ferring-Appel D, Hentze MW and Galy B:
Cell-autonomous and systemic context-dependent functions of iron
regulatory protein 2 in mammalian iron metabolism. Blood.
113:679–687. 2009. View Article : Google Scholar
|
|
13
|
Jézéquel P, Campion L, Spyratos F,
Loussouarn D, Campone M, Guérin-Charbonnel C, Joalland MP, André J,
Descotes F, Grenot C, et al: Validation of tumor-associated
macrophage ferritin light chain as a prognostic biomarker in
node-negative breast cancer tumors: A multicentric 2004 national
PHRC study. Int J Cancer. 131:426–437. 2012. View Article : Google Scholar
|
|
14
|
Levi S, Luzzago A, Cesareni G, Cozzi A,
Franceschinelli F, Albertini A and Arosio P: Mechanism of ferritin
iron uptake: Activity of the H-chain and deletion mapping of the
ferro-oxidase site. A study of iron uptake and ferro-oxidase
activity of human liver, recombinant H-chain ferritins, and of two
H-chain deletion mutants. J Biol Chem. 263:18086–18092.
1988.PubMed/NCBI
|
|
15
|
Alkhateeb AA and Connor JR: The
significance of ferritin in cancer: Anti-oxidation, inflammation
and tumorigenesis. Biochim Biophys Acta. 1836:245–254.
2013.PubMed/NCBI
|
|
16
|
Fargion S, Fracanzani AL, Brando B, Arosio
P, Levi S and Fiorelli G: Specific binding sites for H-ferritin on
human lymphocytes: Modulation during cellular proliferation and
potential implication in cell growth control. Blood. 78:1056–1061.
1991.PubMed/NCBI
|
|
17
|
Cohen LA, Gutierrez L, Weiss A,
Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, Sougrat R, Morgenstern
A, Galy B, Hentze MW, et al: Serum ferritin is derived primarily
from macrophages through a nonclassical secretory pathway. Blood.
116:1574–1584. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li JY, Paragas N, Ned RM, Qiu A, Viltard
M, Leete T, Drexler IR, Chen X, Sanna-Cherchi S, Mohammed F, et al:
Scara5 is a ferritin receptor mediating non-transferrin iron
delivery. Dev Cell. 16:35–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Madhankumar AB, Slagle-Webb B,
Sheehan JM, Surguladze N and Connor JR: Heavy chain ferritin siRNA
delivered by cationic liposomes increases sensitivity of cancer
cells to chemotherapeutic agents. Cancer Res. 71:2240–2249. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shpyleva SI, Tryndyak VP, Kovalchuk O,
Starlard-Davenport A, Chekhun VF, Beland FA and Pogribny IP: Role
of ferritin alterations in human breast cancer cells. Breast Cancer
Res Treat. 126:63–71. 2011. View Article : Google Scholar
|
|
21
|
Eshhar Z, Order SE and Katz DH: Ferritin,
a Hodgkin's disease associated antigen. Proc Natl Acad Sci USA.
71:3956–3960. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Keizer HG, Pinedo HM, Schuurhuis GJ and
Joenje H: Doxorubicin (adriamycin): A critical review of free
radical-dependent mechanisms of cytotoxicity. Pharmacol Ther.
47:219–231. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Knovich MA, Storey JA, Coffman LG, Torti
SV and Torti FM: Ferritin for the clinician. Blood Rev. 23:95–104.
2009. View Article : Google Scholar :
|
